XDATA – August 29th 2014
Nanospectra Biosciences sold a total of $800,000 in a non-brokered equity investment round. The transaction which started a week ago, garnered the support of fifteen investors. A total of six unregistered securities offerings closed by the company raised an estimated $7.9 million.
The company is focused on the development of AuroLase therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The AuroLase therapy process involves infusing a single dose of nanoshell particles into the patient’s blood stream via intravenous injection. After 12 to 24 hours, enough time for the particles to accumulate inside the tumor, a special laser is used to illuminate and heat the particles within the tumor.
The company, headquartered in Houston TX, is led by David Jorden (CEO). Nanospectra Biosciences elected to keep its revenues undisclosed.
The executive team includes Glenn Goodrich and Patrick Pace.
The board of directors includes Bradley Nyberg, David Bristol and Jennifer West.
The company has raised an estimated total of $8.7 million via private unregistered security offerings.
Company: Nanospectra Biosciences
Industry: Other Health Care
Amount offered: $800,000
Amount placed: $800,000
First sale: 08-22-2014
Data as of: 08-29-2014